The Cooper Companies delivered a solid QQ4 2024 performance characterized by record quarterly revenue of $1.018 billion, up 10% year over year and 7% organically, supported by continued strength in CooperVision's daily silicone hydrogel portfolio and a resilient CooperSurgical in fertility. Management highlighted margin expansion driven by price realization and efficiency gains, with non-GAAP EPS of $1.04 for the quarter and full-year 2024 results that featured record group revenues of $3.9 billion, up 8% year over year and organically. For fiscal 2025, the company provided disciplined guidance: consolidated revenues of $4.08-4.158 billion, representing roughly 6-8% organic growth, with gross margins and operating margins set to expand (10-12% constant currency operating income growth). FX headwinds remained a headwind to earnings (~4%), and Paragard faced ongoing competitive pressure, guiding a modest range for Paragard in FY25. The company also signaled capacity expansion and continued product launches (including MyDay Energys, MyDay torics, and expanded MiSight adoption) as key levers for sustaining outperformance relative to a growing market, particularly in the U.S. and Asia Pacific. The combination of pricing power, capacity investments, and portfolio diversification supports an constructive multi-year growth trajectory, albeit with near-term volatility from product cycles, channel inventory dynamics, and macro headwinds.